This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Urovant Sciences Ltd.
Urovant Sciences Ltd., a leading biopharmaceutical company headquartered in Great Britain, focuses on developing innovative therapies for urological conditions. Founded in 2018, Urovant has quickly established itself in the healthcare industry, particularly in the field of urology, with a commitment to improving patient outcomes through advanced treatments. The company’s flagship product, vibegron, is a novel oral medication designed to treat overactive bladder, setting it apart with its unique mechanism of action. Urovant’s dedication to research and development has positioned it as a key player in the urology market, with a growing portfolio aimed at addressing unmet medical needs. With a strong operational presence in North America and Europe, Urovant Sciences continues to make significant strides in enhancing the quality of life for patients suffering from urological disorders.
DitchCarbon Score
How does Urovant Sciences Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Urovant Sciences Ltd.'s score of 38 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Urovant Sciences Ltd., headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Sumitomo Pharma Co., Ltd., which influences its climate commitments and initiatives. While Urovant Sciences Ltd. has not established its own reduction targets or climate pledges, it inherits sustainability initiatives from its parent company, Sumitomo Pharma Co., Ltd. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are cascaded from the second level of the corporate family relationship. As Urovant Sciences Ltd. continues to align with its parent company's sustainability goals, it remains focused on contributing to broader industry efforts to mitigate climate change, although specific targets and achievements at the subsidiary level are not currently available.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 41,805,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | - | - |
| Scope 2 | 38,906,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 35,270,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Urovant Sciences Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
